{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T23:09:49Z","timestamp":1788217789790,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"none"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s00277-025-06468-x","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T01:34:50Z","timestamp":1751506490000},"page":"4213-4221","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Second allogeneic transplantation in relapsed acute leukemia \u2013 a risk worth taking?"],"prefix":"10.1007","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5215-5264","authenticated-orcid":false,"given":"Patrycja","family":"Zieli\u0144ska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Gruenpeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Wieczorkiewicz-Kabut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Bia\u0142as","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kocl\u0119ga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabela","family":"Noster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabela","family":"Szewczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinga","family":"Boral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Wi\u015bniewska-Pi\u0105ty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Butrym","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaros\u0142aw","family":"Czy\u017c","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Lutwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Helbig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"issue":"2","key":"6468_CR1","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1097\/MOH.0b013e3283257a87","volume":"16","author":"LM Arfons","year":"2009","unstructured":"Arfons LM, Tomblyn M, Rocha V, Lazarus HM (2009) Second hematopoietic stem cell transplantation in myeloid malignancies. Curr Opin Hematol 16(2):112\u2013123. https:\/\/doi.org\/10.1097\/MOH.0b013e3283257a87","journal-title":"Curr Opin Hematol"},{"issue":"8","key":"6468_CR2","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1038\/s41375-024-02318-3","volume":"38","author":"O Penack","year":"2024","unstructured":"Penack O, Abouqateb M, Peczynski C, Boreland W, Kr\u00f6ger N, Zeiser R, Ciceri F, Schroeder T, Dreger P, Passweg J, Schetelig J, Stelljes M, Blau IW, Franke GN, Riesner K, Schoemans H, Moiseev I, Peric Z (2024) How risky is a second allogeneic stem cell transplantation? Leukemia 38(8):1799\u20131807. https:\/\/doi.org\/10.1038\/s41375-024-02318-3","journal-title":"Leukemia"},{"issue":"1","key":"6468_CR3","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41408-024-01060-4","volume":"14","author":"AK Schm\u00e4lter","year":"2024","unstructured":"Schm\u00e4lter AK, Ngoya M, Galimard JE, Bazarbachi A, Finke J, Kr\u00f6ger N, Bornh\u00e4user M, Stelljes M, St\u00f6lzel F, Tischer J, Schroeder T, Dreger P, Blau IW, Savani B, Giebel S, Esteve J, Nagler A, Schmid C, Ciceri F, Mohty M (2024) Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients. Blood Cancer J 14(1):76. https:\/\/doi.org\/10.1038\/s41408-024-01060-4","journal-title":"Blood Cancer J"},{"issue":"12","key":"6468_CR4","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1038\/bmt.2015.186","volume":"50","author":"T Ruutu","year":"2015","unstructured":"Ruutu T, de Wreede LC, van Biezen A, Brand R, Mohty M, Dreger P, Duarte R, Peters C, Garderet L, Sch\u00f6nland S, Gratwohl A, Niederwieser D, de Witte T, Kr\u00f6ger N, European Society for Blood and Marrow Transplantation (EBMT) (2015) Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT. Bone Marrow Transpl 50(12):1542\u20131550. https:\/\/doi.org\/10.1038\/bmt.2015.186","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"6468_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.transci.2016.01.020","volume":"54","author":"HS G\u00f6ksoy","year":"2016","unstructured":"G\u00f6ksoy HS, Arat M (2016) The use of second allogeneic hematopoietic stem cell transplantation for hematologic malignancies relapsed after the first: does it worth to do? Transfus Apher Sci 54(1):91\u201398. https:\/\/doi.org\/10.1016\/j.transci.2016.01.020","journal-title":"Transfus Apher Sci"},{"key":"6468_CR6","doi-asserted-by":"publisher","unstructured":"Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1976) Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 33(4):451-8. https:\/\/doi.org\/10.1111\/j.1365-2141.1976.tb03563.x","DOI":"10.1111\/j.1365-2141.1976.tb03563.x"},{"issue":"5","key":"6468_CR7","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstr\u00f6m-Lindberg E, Tefferi A, Bloomfield CD (2009) The 2008 revision of the world health organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114(5):937\u2013951. https:\/\/doi.org\/10.1182\/blood-2009-03-209262","journal-title":"Blood"},{"issue":"17","key":"6468_CR8","doi-asserted-by":"publisher","first-page":"5122","DOI":"10.1182\/bloodadvances.2023010173","volume":"7","author":"E Attardi","year":"2023","unstructured":"Attardi E, Savi A, Borsellino B, Piciocchi A, Cipriani M, Ottone T, Fabiani E, Divona M, Travaglini S, Pascale MR, Awada H, Durmaz A, Visconte V, Della Porta MG, Venditti A, Maciejewski JP, Gurnari C, Voso MT (2023) Applicability of 2022 classifications of acute myeloid leukemia in the real-world setting. Blood Adv 7(17):5122\u20135131. https:\/\/doi.org\/10.1182\/bloodadvances.2023010173","journal-title":"Blood Adv"},{"issue":"23","key":"6468_CR9","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","volume":"123","author":"P Armand","year":"2014","unstructured":"Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, Maziarz RT, Antin JH, Soiffer RJ, Weisdorf DJ, Rizzo JD, Horowitz MM, Saber W (2014) Validation and refinement of the disease risk index for allogeneic stem cell transplantation. Blood 123(23):3664\u20133671. https:\/\/doi.org\/10.1182\/blood-2014-01-552984","journal-title":"Blood"},{"key":"6468_CR10","doi-asserted-by":"publisher","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, Storer B (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106(8):2912-9.\u00a0https:\/\/doi.org\/10.1182\/blood-2005-05-2004","DOI":"10.1182\/blood-2005-05-2004"},{"issue":"12","key":"6468_CR11","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, Apperley J, Slavin S, Pasquini M, Sandmaier BM, Barrett J, Blaise D, Lowski R, Horowitz M (2009) Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl 15(12):1628\u20131633","journal-title":"Biol Blood Marrow Transpl"},{"key":"6468_CR12","doi-asserted-by":"crossref","unstructured":"Valcarcel D, Sureda A (2019) Graft failure. In: The EBMT Handbook. Hematopoietic stem cell transplantation and cellular therapies. Carreras E, Dufour C, Mohty M, Kroger N, eds. Springer Open. : 307\u2013313","DOI":"10.1007\/978-3-030-02278-5_41"},{"key":"6468_CR13","doi-asserted-by":"crossref","unstructured":"Holler E, Hildegerad G, Zeiser R (2019) Acute graft-versus-host disease. In: The EBMT Handbook. Hematopoietic stem cell transplantation and cellular therapies. Carreras E, Dufour C, Mohty M, Kroger N, eds. Springer Open. 323\u2013330","DOI":"10.1007\/978-3-030-02278-5_43"},{"key":"6468_CR14","doi-asserted-by":"publisher","unstructured":"Schmid C, Labopin M, Nagler A, Bornh\u00e4user M, Finke J, Fassas A, Volin L, G\u00fcrman G, Maertens J, Bordigoni P, Holler E, Ehninger G, Polge E, Gorin NC, Kolb HJ, Rocha V, EBMT Acute Leukemia Working Party (2007) Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol 25(31):4938-45.\u00a0https:\/\/doi.org\/10.1200\/JCO.2007.11.6053","DOI":"10.1200\/JCO.2007.11.6053"},{"issue":"26","key":"6468_CR15","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1200\/JCO.2012.44.7961","volume":"31","author":"M Christopeit","year":"2013","unstructured":"Christopeit M, Kuss O, Finke J, Bacher U, Beelen DW, Bornh\u00e4user M, Schwerdtfeger R, Bethge WA, Basara N, Gramatzki M, Tischer J, Kolb HJ, Uharek L, Meyer RG, Bunjes D, Scheid C, Martin H, Niederwieser D, Kr\u00f6ger N, Bertz H, Schrezenmeier H, Schmid C (2013) Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change. J Clin Oncol 31(26):3259\u20133271. https:\/\/doi.org\/10.1200\/JCO.2012.44.7961","journal-title":"J Clin Oncol"},{"key":"6468_CR16","doi-asserted-by":"publisher","unstructured":"Bosi A, Laszlo D, Labopin M, Reffeirs J, Michallet M, Gluckman E, Alessandrino PE, Locatelli F, Vernant JP, Sierra J, Jouet JP, Frassoni F, Acute Leukemia Working Party of the European Blood and Marrow Transplant Group (2001) Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol 19(16):3675-84. https:\/\/doi.org\/10.1200\/JCO.2001.19.16.3675","DOI":"10.1200\/JCO.2001.19.16.3675"},{"issue":"9","key":"6468_CR17","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1001\/jamaoncol.2018.2091","volume":"4","author":"MA Kharfan-Dabaja","year":"2018","unstructured":"Kharfan-Dabaja MA, Labopin M, Polge E, Nishihori T, Bazarbachi A, Finke J, Stadler M, Ehninger G, Lioure B, Schaap N, Afanasyev B, Yeshurun M, Isaksson C, Maertens J, Chalandon Y, Schmid C, Nagler A, Mohty M (2018) Association of second allogeneic hematopoietic cell transplant vs donor lymphocyte infusion with overall survival in patients with acute myeloid leukemia relapse. JAMA Oncol 4(9):1245\u20131253","journal-title":"JAMA Oncol"},{"issue":"12","key":"6468_CR18","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1038\/bmt.2015.193","volume":"50","author":"G Andreola","year":"2015","unstructured":"Andreola G, Labopin M, Beelen D, Chevallier P, Tabrizi R, Bosi A, Michallet M, Santarone S, Ehninger G, Polge E, Laszlo D, Schmid C, Nagler A, Mohty M (2015) Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of \u2a7e10 years. Bone Marrow Transpl 50(12):1508\u20131512. https:\/\/doi.org\/10.1038\/bmt.2015.193","journal-title":"Bone Marrow Transpl"},{"issue":"24","key":"6468_CR19","doi-asserted-by":"publisher","first-page":"6283","DOI":"10.1182\/bloodadvances.2020003418","volume":"4","author":"O Penack","year":"2020","unstructured":"Penack O, Peczynski C, Mohty M, Yakoub-Agha I, Styczynski J, Montoto S, Duarte RF, Kr\u00f6ger N, Schoemans H, Koenecke C, Peric Z, Basak GW (2020) How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT. Blood Adv 4(24):6283\u20136290. https:\/\/doi.org\/10.1182\/bloodadvances.2020003418","journal-title":"Blood Adv"},{"issue":"8","key":"6468_CR20","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/s41409-023-01985-7","volume":"58","author":"G Filippini Vel\u00e1zquez","year":"2023","unstructured":"Filippini Vel\u00e1zquez G, Labopin M, Tischer J, Raiola AM, Angelucci E, Kulagin AD, Galieni P, Berm\u00fadez A, Bulabois CE, Kr\u00f6ger N, D\u00edez-Mart\u00edn JL, Kwon M, Nagler A, Schmid C, Ciceri F, Mohty M (2023) Second haploidentical stem cell transplantation (HAPLO-SCT2) after relapse from a first HAPLO-SCT in acute leukaemia-a study on behalf of the acute leukaemia working party (ALWP) of the European society for blood and marrow transplantation (EBMT). Bone Marrow Transpl 58(8):907\u2013915. https:\/\/doi.org\/10.1038\/s41409-023-01985-7","journal-title":"Bone Marrow Transpl"},{"issue":"8","key":"6468_CR21","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jtct.2021.05.007","volume":"27","author":"FF Yalniz","year":"2021","unstructured":"Yalniz FF, Saliba RM, Greenbaum U, Ramdial J, Popat U, Oran B, Alousi A, Olson A, Alatrash G, Marin D, Rezvani K, Hosing C, Im J, Mehta R, Qazilbash M, Joseph JJ, Rondon G, Kanagal-Shamanna R, Shpall E, Champlin R, Kebriaei P (2021) Outcomes of second allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia. Transpl Cell Ther 27(8):689\u2013695","journal-title":"Transpl Cell Ther"},{"issue":"1","key":"6468_CR22","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.bbmt.2014.10.006","volume":"21","author":"CN Duncan","year":"2015","unstructured":"Duncan CN, Majhail NS, Brazauskas R, Wang Z, Cahn JY, Frangoul HA, Hayashi RJ, Hsu JW, Kamble RT, Kasow KA, Khera N, Lazarus HM, Loren AW, Marks DI, Maziarz RT, Mehta P, Myers KC, Norkin M, Pidala JA, Porter DL, Reddy V, Saber W, Savani BN, Schouten HC, Steinberg A, Wall DA, Warwick AB, Wood WA, Yu LC, Jacobsohn DA, Sorror ML (2015) Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromes. Biol Blood Marrow Transpl 21(1):151\u2013158. https:\/\/doi.org\/10.1016\/j.bbmt.2014.10.006","journal-title":"Biol Blood Marrow Transpl"},{"issue":"24","key":"6468_CR23","doi-asserted-by":"publisher","first-page":"6475","DOI":"10.1158\/1078-0432.CCR-20-3134","volume":"26","author":"A Bazarbachi","year":"2020","unstructured":"Bazarbachi A, Schmid C, Labopin M, Beelen D, Wolfgang Blau I, Potter V, Niittyvuopio R, Soci\u00e9 G, Blaise D, Sanz J, Ciceri F, Abou Dalle I, Spyridonidis A, Bug G, Esteve J, Savani BN, Nagler A, Mohty M (2020) Evaluation of trends and prognosis over time in patients with AML relapsing after allogeneic hematopoietic cell transplant reveals improved survival for young patients in recent years. Clin Cancer Res 26(24):6475\u20136482. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3134","journal-title":"Clin Cancer Res"},{"issue":"5","key":"6468_CR24","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1038\/s41409-020-01163-z","volume":"56","author":"M Yanada","year":"2021","unstructured":"Yanada M, Konuma T, Yamasaki S, Kondo T, Fukuda T, Shingai N, Sawa M, Ozawa Y, Tanaka M, Uchida N, Nakamae H, Katayama Y, Matsuoka KI, Kimura T, Kanda Y, Ichinohe T, Atsuta Y, Yano S (2021) Relapse of acute myeloid leukemia after allogeneic hematopoietic cell transplantation: clinical features and outcomes. Bone Marrow Transpl 56(5):1126\u20131133. https:\/\/doi.org\/10.1038\/s41409-020-01163-z","journal-title":"Bone Marrow Transpl"},{"issue":"11","key":"6468_CR25","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.jtct.2022.08.008","volume":"28","author":"MA Kharfan-Dabaja","year":"2022","unstructured":"Kharfan-Dabaja MA, Reljic T, Yassine F, Nishihori T, Kumar A, Tawk MM, Keller K, Ayala E, Savani B, Mohty M, Aljurf M, Saber W (2022) Efficacy of a second allogeneic hematopoietic cell transplant in relapsed acute myeloid leukemia: results of a systematic review and Meta-Analysis. Transpl Cell Ther 28(11):767","journal-title":"Transpl Cell Ther"},{"key":"6468_CR26","doi-asserted-by":"publisher","unstructured":"Schuler E, Wagner-Drouet EM, Ajib S, Bug G, Crysandt M, Dressler S, Hausmann A, Heidenreich D, Hirschb\u00fchl K, Hoepting M, Jost E, Kaivers J, Klein S, Koldehoff M, Kordelas L, Kriege O, M\u00fcller LP, Rautenberg C, Schaffrath J, Schmid C, Wolff D, Haas R, Bornh\u00e4user M, Schroeder T, Kobbe G, German Cooperative Transplant Study Group (2021) Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group. Ann Hematol 100(4):959\u2013968. https:\/\/doi.org\/10.1007\/s00277-020-04321-x. Epub 2020 Nov 16. Erratum in: Ann Hematol. 2021;100(8):2141\u20132142.\u00a0https:\/\/doi.org\/10.1007\/s00277-021-04564-2","DOI":"10.1007\/s00277-020-04321-x"},{"issue":"8","key":"6468_CR27","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.3390\/cancers12082255","volume":"12","author":"C Rautenberg","year":"2020","unstructured":"Rautenberg C, Bergmann A, Germing U, Fischermanns C, Pechtel S, Kaivers J, J\u00e4ger P, Schuler E, Haas R, Kobbe G, Schroeder T (2020) Prediction of response and survival following treatment with Azacitidine for relapse of acute myeloid leukemia and myelodysplastic syndromes after allogeneic hematopoietic stem cell transplantation. Cancers (Basel) 12(8):2255. https:\/\/doi.org\/10.3390\/cancers12082255","journal-title":"Cancers (Basel)"},{"issue":"4","key":"6468_CR28","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/ejh.12832","volume":"98","author":"C Rautenberg","year":"2017","unstructured":"Rautenberg C, Nachtkamp K, Dienst A, Schmidt PV, Heyn C, Kondakci M, Germing U, Haas R, Kobbe G, Schroeder T (2017) Sorafenib and Azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCT. Eur J Haematol 98(4):348\u2013354. https:\/\/doi.org\/10.1111\/ejh.12832","journal-title":"Eur J Haematol"},{"issue":"1","key":"6468_CR29","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12943-023-01889-6","volume":"22","author":"T Sauerer","year":"2023","unstructured":"Sauerer T, Vel\u00e1zquez GF, Schmid C (2023) Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: immune escape mechanisms and current implications for therapy. Mol Cancer 22(1):180. https:\/\/doi.org\/10.1186\/s12943-023-01889-6","journal-title":"Mol Cancer"},{"issue":"6","key":"6468_CR30","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1053\/j.seminoncol.2012.09.009","volume":"39","author":"L Vago","year":"2012","unstructured":"Vago L, Toffalori C, Ciceri F, Fleischhauer K (2012) Genomic loss of mismatched human leukocyte antigen and leukemia immune escape from haploidentical graft-versus-leukemia. Semin Oncol. 39(6):707\u201315. https:\/\/doi.org\/10.1053\/j.seminoncol.2012.09.009","journal-title":"Semin Oncol."},{"issue":"4","key":"6468_CR31","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41591-019-0400-z","volume":"25","author":"C Toffalori","year":"2019","unstructured":"Toffalori C, Zito L, Gambacorta V, Riba M, Oliveira G, Bucci G, Barcella M, Spinelli O, Greco R, Crucitti L, Cieri N, Noviello M, Manfredi F, Montaldo E, Ostuni R, Naldini MM, Gentner B, Waterhouse M, Zeiser R, Finke J, Hanoun M, Beelen DW, Gojo I, Luznik L, Onozawa M, Teshima T, Devillier R, Blaise D, Halkes CJM, Griffioen M, Carrabba MG, Bernardi M, Peccatori J, Barlassina C, Stupka E, Lazarevic D, Tonon G, Rambaldi A, Cittaro D, Bonini C, Fleischhauer K, Ciceri F, Vago L (2019) Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. Nat Med 25(4):603\u2013611. https:\/\/doi.org\/10.1038\/s41591-019-0400-z","journal-title":"Nat Med"},{"issue":"3","key":"6468_CR32","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.bbmt.2015.11.012","volume":"22","author":"G Orti","year":"2016","unstructured":"Orti G, Sanz J, Bermudez A, Caballero D, Martinez C, Sierra J, Cabrera Marin JR, Espigado I, Solano C, Ferr\u00e0 C, Garc\u00eda-Noblejas A, Jimenez S, Sampol A, Ya\u00f1ez L, Garc\u00eda-Guti\u00e9rrez V, Pascual MJ, Jurado M, Moraleda JM, Valcarcel D, Sanz MA, Carreras E, Duarte RF (2016) Outcome of second allogeneic hematopoietic cell transplantation after relapse of myeloid malignancies following allogeneic hematopoietic cell transplantation: A retrospective cohort on behalf of the grupo Espa\u00f1ol de Trasplante hematopoyetico. Biol Blood Marrow Transpl 22(3):584\u2013588","journal-title":"Biol Blood Marrow Transpl"},{"issue":"3","key":"6468_CR33","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/bjh.17426","volume":"193","author":"MA Kharfan-Dabaja","year":"2021","unstructured":"Kharfan-Dabaja MA, Labopin M, Brissot E, Kroger N, Finke J, Ciceri F, Deconinck E, Blaise D, Chevallier P, Gramatzki M, Ganser A, Stelljes M, Edinger M, Savani B, Ruggeri A, Sanz J, Nagler A, Mohty M (2021) Second allogeneic Haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia. Br J Haematol 193(3):592\u2013601. https:\/\/doi.org\/10.1111\/bjh.17426","journal-title":"Br J Haematol"},{"key":"6468_CR34","doi-asserted-by":"publisher","unstructured":"Nagler A, Peczynski C, Dholaria B, Labopin M, Valerius T, Dreger P, Kr\u00f6ger N, Reinhardt HC, Finke J, Franke GN, Ciceri F, Verbeek M, Blau IW, Bornh\u00e4user M, Spyridonidis A, Bug G, Bazarbachi A, Schmid C, Yakoub-Agha I, Savani BN, Mohty M (2022) Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia. Bone Marrow Transplant 57(7):1116\u20131123. https:\/\/doi.org\/10.1038\/s41409-022-01693-8. Epub 2022 Apr 30. Erratum in: Bone Marrow Transplant. 2022;57(12):1854.\u00a0https:\/\/doi.org\/10.1038\/s41409-022-01834-z","DOI":"10.1038\/s41409-022-01693-8"},{"key":"6468_CR35","doi-asserted-by":"publisher","unstructured":"Vrhovac R, Labopin M, Ciceri F, Finke J, Holler E, Tischer J, Lioure B, Gribben J, Kanz L, Blaise D, Dreger P, Held G, Arnold R, Nagler A, Mohty M, Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) (2016) Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes. Bone Marrow Transplant 51(2):186\u2009\u2013\u200993. https:\/\/doi.org\/10.1038\/bmt.2015.221","DOI":"10.1038\/bmt.2015.221"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06468-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06468-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06468-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T07:49:01Z","timestamp":1757663341000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06468-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["6468"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06468-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]},"assertion":[{"value":"8 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a retrospective study and the consent of Ethics Committee was not required. Allogeneic stem cell transplantation remains a standard of care for hematological patients as per EBMT recommendations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all patients and is available per request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}